Galecto, Inc. (GLTO)
NASDAQ$4.05
Market Cap
$5.33M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
603 of 924
Rank in Industry
346 of 527
Insider Buys Sum
Cluster
Trading
Trading
Insider Buys
Quantity
Quantity
Historical
Profitability
Profitability
Investor
Ownership
Ownership
Largest Insider Buys in Sector
GLTO Insider Trading Activity
GLTO Median Price and Trade Amounts History Chart
Statistics of Insider Transactions
Amount of Insider Buys and Sells
Buys | $0 | 0 | 0 |
Sells | $11,617 | 3 | 100 |
Related Transactions
| Firmani Lori | Interim CFO | 0 | $0 | 1 | $1,469 | $-1,469 |
| Winslow Garrett | General Counsel | 0 | $0 | 1 | $2,638 | $-2,638 |
| Schambye Hans T. | Chief Executive Officer | 0 | $0 | 1 | $7,510 | $-7,510 |
About Galecto, Inc.
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; and GB1211, a selective oral galectin-3 …
Insider Activity of Galecto, Inc.
Over the last 12 months, insiders at Galecto, Inc. have bought $0 and sold $11,617 worth of Galecto, Inc. stock.
On average, over the past 5 years, insiders at Galecto, Inc. have bought $14.71M and sold $1.22M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 5,000 shares for transaction amount of $10,750 was made by Schambye Hans T. (Chief Executive Officer) on 2022‑03‑22.
List of Insider Buy and Sell Transactions, Galecto, Inc.
| 2025-01-03 | Sale | Schambye Hans T. | Chief Executive Officer | 1,341 0.1037% | $5.60 | $7,510 | -17.72% | |
| 2025-01-03 | Sale | Winslow Garrett | General Counsel | 471 0.0364% | $5.60 | $2,638 | -17.72% | |
| 2025-01-03 | Sale | Firmani Lori | Interim CFO | 261 0.0203% | $5.63 | $1,469 | -17.72% | |
| 2023-08-15 | Sale | ORBIMED ADVISORS LLC | 10 percent owner | 822,680 3.5684% | $0.75 | $617,010 | -7.48% | |
| 2023-07-31 | Sale | ORBIMED ADVISORS LLC | 10 percent owner | 209,400 0.8023% | $3.00 | $628,200 | -79.55% | |
| 2023-07-25 | Sale | ORBIMED ADVISORS LLC | 10 percent owner | 39,200 0.1462% | $2.92 | $114,464 | -79.34% | |
| 2023-07-13 | Sale | ORBIMED ADVISORS LLC | 10 percent owner | 194,700 0.7339% | $2.40 | $467,280 | -74.19% | |
| 2023-04-17 | Sale | ORBIMED ADVISORS LLC | 10 percent owner | 12,429 0.0461% | $1.97 | $24,485 | -66.21% | |
| 2023-04-17 | Sale | ORBIMED ADVISORS LLC | 10 percent owner | 13,089 0.0485% | $1.97 | $25,785 | -66.21% | |
| 2023-04-14 | Sale | ORBIMED ADVISORS LLC | 10 percent owner | 39,355 0.1501% | $1.86 | $73,200 | -63.13% | |
| 2023-04-14 | Sale | ORBIMED ADVISORS LLC | 10 percent owner | 41,446 0.158% | $1.86 | $77,090 | -63.13% | |
| 2023-04-13 | Sale | ORBIMED ADVISORS LLC | 10 percent owner | 13,243 0.0519% | $1.82 | $24,102 | -61.26% | |
| 2023-04-13 | Sale | ORBIMED ADVISORS LLC | 10 percent owner | 13,946 0.0546% | $1.82 | $25,382 | -61.26% | |
| 2023-04-12 | Sale | ORBIMED ADVISORS LLC | 10 percent owner | 2,363 0.0093% | $1.81 | $4,277 | -60.83% | |
| 2023-04-11 | Sale | ORBIMED ADVISORS LLC | 10 percent owner | 13,946 0.0543% | $1.82 | $25,382 | -61.41% | |
| 2023-04-10 | Sale | ORBIMED ADVISORS LLC | 10 percent owner | 51,228 0.1984% | $1.79 | $91,698 | -60.81% | |
| 2023-04-06 | Sale | ORBIMED ADVISORS LLC | 10 percent owner | 9,665 0.0396% | $2.00 | $19,330 | -62.87% | |
| 2023-04-05 | Sale | ORBIMED ADVISORS LLC | 10 percent owner | 92,965 0.3672% | $2.18 | $202,664 | -67.11% | |
| 2022-03-22 | Schambye Hans T. | Chief Executive Officer | 5,000 0.0194% | $2.15 | $10,750 | -12.79% | ||
| 2022-03-22 | Lindmark Bertil | Chief Medical Officer | 14,604 0.057% | $2.16 | $31,545 | -12.79% |
Total: 33
*Gray background shows transactions not older than one year
Insider Historical Profitability
<0.0001%
| Schambye Hans T. | Chief Executive Officer | 3397 0.2579% | $13,757.85 | 3 | 1 | <0.0001% |
| Winslow Garrett | General Counsel | 1009 0.0766% | $4,086.45 | 2 | 1 | <0.0001% |
| Khuong Chau Quang | 2579657 195.8752% | $10.45M | 1 | 0 | ||
| Novo Holdings A/S | 10 percent owner | 2497791 189.6591% | $10.12M | 1 | 0 | |
| Christgau Stephan | director | 546136 41.4685% | $2.21M | 1 | 0 |
*Gray background shows insiders who have made transactions during last year
Historical Insider Profitability vs. Competitors
$18,881,323 | 88 | -48.96% | $4.47M | |
$296,936 | 37 | -18.12% | $4M | |
$523,320 | 24 | 94.37% | $7.01M | |
$31,129 | 22 | -11.96% | $6.19M | |
$51,865 | 17 | -38.70% | $6.16M |
GLTO Institutional Investors: Active Positions
| Increased Positions | 5 | +38.46% | 20,188 | +15.69% |
| Decreased Positions | 5 | -38.46% | 6,782 | -5.27% |
| New Positions | 3 | New | 12,819 | New |
| Sold Out Positions | 3 | Sold Out | 384 | Sold Out |
| Total Postitions | 13 | company.total | 142,062 | +10.42% |
GLTO Ownership Change vs Market
Institutional Investor Ownership
Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Active Shareholders
| Novo Holdings A/S | $438.00 | 9.99% | 99,913 | 0 | 0% | 2024-12-31 |
| Renaissance Technologies Llc | $66.00 | 1.5% | 15,044 | -6,338 | -29.64% | 2024-12-31 |
| Squarepoint Ops Llc | $56.00 | 1.27% | 12,701 | +12,701 | New | 2024-12-31 |
| Ubs Group Ag | $55.00 | 1.25% | 12,467 | +7,368 | +144.5% | 2024-12-31 |
| Bank Of America Corp /De/ | $5.00 | 0.12% | 1,226 | +<1 | +0.08% | 2024-12-31 |
| Blackrock, Inc. | $2.00 | 0.05% | 490 | 0 | 0% | 2024-12-31 |
| Morgan Stanley | $0 | 0.01% | 100 | -60 | -37.5% | 2024-12-31 |
| Jpmorgan Chase & Co | $0 | 0.01% | 100 | +100 | New | 2024-12-31 |
| Sbi Securities Co., Ltd. | $0 | <0.01% | 18 | +18 | New | 2024-12-31 |
| Group One Trading Llc | $0 | 0% | 3 | 0 | 0% | 2024-12-31 |
Financial Ratios
Summary
Comparison with Competitors
Analyst Recommendations
Analyst Price Targets
Screener Ideas
Dividend StocksBlue Chip StocksDefensive StocksGrowth StocksValue StocksCyclical StocksPenny StocksPrismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.